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Abstract
Tumors are frequently characterized by genomically and phenotypically distinct cancer cell 
subpopulations within the same tumor or between tumor lesions, a phenomenon termed tumor 
heterogeneity. These diverse cancer cell populations pose a major challenge to targeted delivery of 
diagnostic and/or therapeutic agents, as the conventional approach of conjugating individual 
ligands to nanoparticles is often unable to facilitate intracellular delivery to the full spectrum of 
cancer cells present in a given tumor lesion or patient. As a result, many cancers are only partial 
suppressed, leading to eventual tumor regrowth and/or the development of drug-resistant tumors. 
Pretargeting (multistep targeting) approaches, which involves administering 1) a cocktail of 
bispecific proteins that can collectively bind to the entirety of a mixed tumor population followed 
by 2) nanoparticles containing therapeutic and/or diagnostic agents that can bind to the bispecific 
proteins accumulated on the surface of target cells offers the potential to overcome many of the 
challenges associated with drug delivery to heterogeneous tumors. Despite its considerable 
success in improving the efficacy of radioimmunotherapy, the pretargeting strategy remains 
underexplored for a majority of nanoparticle therapeutics applications, especially for targeted 
delivery to heterogeneous tumors. In this review, we will present concepts in tumor heterogeneity, 
the shortcomings of conventional targeted systems, lessons learned from pretargeted 
radioimmunotherapy, and important considerations for harnessing the pretargeting strategy to 
improve nanoparticle delivery to heterogeneous tumors.
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Introduction
Targeted drug delivery for cancer offers the potential to significantly improve the 
therapeutic index of anticancer agents by increasing drug concentration at tumor sites while 
reducing side effects and toxicity in non-targeted tissues. A long-standing approach in the 
field has been to exploit the leaky tumor vasculature in tumor tissues by encapsulating 
therapeutic cargo into nanoparticles that remain sufficiently stable when introduced to the 
systemic circulation in order to reach and extravasate into cancer tissues. To further 
facilitate selective delivery into cancer cells, many researchers have functionalized 
nanoparticles with ligands that bind specific receptors on cancer cells, a strategy commonly 
referred to as “active” targeting [1]. Unfortunately, the accumulation of both ligand-free and 
ligand-conjugated systems in tumors is generally modest at best, limiting the efficacy of 
various therapies against cancer [2, 3].
Due to advances in the genetic and phenotypic analysis of tumors, tumor heterogeneity has 
recently emerged as yet another biological barrier that could limit efficient distribution, 
retention, and uptake of ligand-conjugated nanoparticles at tumor sites [2, 4, 5]. Tumor 
heterogeneity also encompasses the highly variable expression of target receptors, both 
intertumorally between patients or different tumors and intratumorally within a given tumor, 
and has been reported for a wide range of human tumors [6, 7]. Due to the absence or 
suboptimal expression of their target receptor on many tumor cell subpopulations, actively 
targeted drug carriers, which typically consist of single-ligand nanoparticles, are unable to 
effectively bind and internalize into the full spectrum of tumor cells present in any particular 
tumor. As noted by Bae et al., “aiming at cancer cells with a single surface marker results in 
aiming at a single population among mixed populations which are constantly changing and 
moving” [2]. Inadequate drug delivery to all cancer cell subpopulations typically results in 
only partial suppression of the cancer and eventually leads to tumor regrowth and/or the 
emergence of therapy-refractory tumor cell populations [8–10]. Thus, targeting strategies 
that can directly address the challenges associated with tumor heterogeneity and enable 
effective delivery of nanoparticles are sorely needed.
One promising targeting strategy is to decouple molecular homing and delivery of 
therapeutics into two separate steps. This approach involves first introducing bispecific 
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proteins (BsPs) that can specificially bind (i.e., “pretarget”) cancer cells, followed by the 
administration of a drug-carrying effector such as a nanoparticle that can be captured by the 
BsPs accumulated on the surface of tumor cells (Figure 1). By introducing multiple distinct 
BsPs, a single effector nanoparticle could in theory bind with molecular specificity to the 
full diversity of cancer cells present in any particular tumor. In this review, we will discuss 
the concept of, important considerations for, and key challenges associated with exploiting 
the pretargeted strategy to enhance the delivery of therapeutics to heterogeneous tumors.
Conventional cancer targeting strategies: passive targeting
In 1986, Matsumura and Maeda discovered that macromolecules can preferentially 
accumulate in tumors due to anatomical and pathophysiological differences between solid 
tumors and healthy tissue [11–13]. Specifically, tumors initiate extensive angiogenesis to 
maintain their rapid growth, but the newly formed blood vessels display abnormal 
architecture including fenestrated endothelial lining of vessel walls [12–14]. The more 
permeable tumor vasculature then allows macromolecules and nanoparticles to extravasate 
from the bloodstream and accumulate in the tumor [13, 14]. Presumably poor lymphatic 
drainage further permits enhanced retention of drug delivery systems within tumors [12, 14]. 
The combination of leaky tumor vasculature and impaired lymphatic drainage constitute the 
phenomenon termed the enhanced permeability and retention (EPR) effect.
Harnessing the EPR phenomenon simply requires nanoparticles to (i) fall within an 
appropriate size range and (ii) evade rapid elimination by the mononuclear phagocytic 
system (MPS). While smaller nanoparticles can naturally extravasate more efficiently than 
larger nanoparticles, most studies suggest the tumor vasculature in mouse xenografts can 
permit extravasation of nanoparticles ranging from 10 to 200 nm in diameter [13, 15–17] 
with some studies reporting EPR of particles up to 500 nm in diameter [14, 18]. In addition 
to size, prolonged circulation kinetics also directly improve the extent of nanoparticle 
extravasation through leaky tumor blood vessels by maximizing the number of times a 
nanoparticle will pass through the tumor vasculature [12, 18]. Polyethylene glycol (PEG) 
was among the first “stealth” polymers used to extend liposome and other nanoparticle 
circulation times by minimizing opsonin adsorption and nanoparticle elimination by MPS 
cells, and PEGylation is the most widely adopted strategy to enhance nanoparticle tumor 
uptake via EPR [12–14, 18]. Other coating polymers used to improve particle circulation 
profiles, and thereby exploit the EPR effect, include flexible, hydrophilic polysaccharides 
such as dextran, hyaluronic acid, and chitosan [19, 20]; synthetic polymers such as polyvinyl 
alcohol [21] and polyvinylpyrrolidone [22]; zwitterionic polymers [23, 24]; and 
polyoxazolines [25]. Indeed, dextran-, hyaluronic acid-, chitosan-, and N-(2-hydroxylpropyl) 
methylacrylamide (HPMA)-coated particles all exhibited improved EPR-mediated tumor 
accumulation due to prolonged circulation [26–29]. Because nanoparticles of the appropriate 
size and with MPS-resistant surface chemistry can naturally achieve a low to moderate level 
of tumor targeting without using specific ligands, these non-molecularly targeted systems 
are frequently classified as passively targeted.
It is important to note that the EPR effect is highly variable and may not be readily 
exploitable for all tumors [30]. For example, hepatocellular and renal cell carcinomas are 
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characterized by high vascular density and exhibit increased EPR effects compared to low 
vascular density pancreatic and prostate cancers that demonstrate diminished EPR effects 
[30, 31]. Additionally, EPR of drug carriers is not observed homogenously throughout 
individual tumors, as the central foci of tumors tend to be characterized by necrotic [30, 32], 
hypoxic [30, 33], and hypovascular areas [12] that do not display the EPR effect [11, 34, 
35]. EPR heterogeneity may also vary between primary tumor and metastases [1]. Therefore, 
harnessing EPR to enhance therapeutic responses in the clinic requires an improved 
understanding of how tumor heterogeneity impacts the EPR effect both within and between 
tumors [1, 13, 30, 36, 37].
Conventional cancer targeting strategies: active targeting
To further improve nanoparticle-based delivery to cancer cells, numerous investigators have 
developed nanoparticles decorated with ligands specific to receptors overexpressed on 
cancer cells, an approach generally termed active targeting [1]. Ligands on actively targeted 
systems are typically grafted to the distal end of polymer chains that are used to coat the 
particles and provide prolong circulation kinetics [18]. These systems are presumed to 
effectively extravasate from the tumor vasculature based on the underlying stealth polymer 
coating, while the presence of ligands can facilitate nanoparticle binding to and subsequent 
internalization into specific tumor cells expressing the corresponding receptor [18, 38]. 
Actively targeted systems were thought to directly address the shortcoming of inefficient 
cellular uptake of passively targeted systems [14, 18]. Numerous targeting ligands have been 
utilized to actively target nanoparticles to cancer cells, including antibodies and antibody 
fragments [39, 40], aptamers [41], peptides [42], proteins, sugars [43], and low molecular 
weight ligands such as folate [44]. For excellent reviews of the features and design of 
actively targeted systems, please refer to [1, 18, 38, 45]
Unfortunately, active targeting systems face several challenges that may limit their efficacy 
in practice. The target cell surface receptors must be highly overexpressed or selectively 
expressed solely on malignant cells, as opposed to healthy cells, to maximize tumor-specific 
delivery [45–47]. Additionally, the choice and density of ligand are critical to optimizing the 
effect of the targeting moiety. Greater ligand density was previously assumed to enhance 
nanoparticle targeting to tumors in vivo due to generally observed improvements in cancer 
cell uptake in vitro [46]. Nevertheless, an increasingly number of studies have shown that 
maximal accumulation of nanoparticles in tumors in vivo is typically achieved with an 
intermediate ligand density [46, 48–51]. For example, increasing the surface aptamer density 
on polymeric nanoparticles actually resulted in reduced tumor accumulation and increased 
particle distribution in the liver [48]. The poor in vivo performance of particles with high 
ligand densities was attributed to ligand shielding or adulteration of the underlying stealth 
polymer coat, leading to rapid MPS clearance and a reduction in the fraction of particles that 
can reach and extravasate into tumors [46, 47].
Tumor heterogeneity and implications for targeted drug delivery systems
Variations in accumulated genetic mutations, which can be further exacerbated by 
alterations in the local tumor microenvironment, frequently lead to genomically distinct 
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subclonal populations within the same tumor or between tumor lesions. This in turn creates a 
phenomenon termed tumor heterogeneity, which describes the functional and phenotypic 
profile differences between cancer cells such as cellular morphology, gene expression, 
metabolism, motility, proliferation, level of drug resistance, and metastatic potential. 
Additionally, the highly variable presence of stromal cell populations such as fibroblasts, 
immune cells, and endothelial cells within tumors is critical in shaping the tumor 
microenvironment [52, 53]. Interactions between the non-tumor cell populations and tumor 
cells contribute to different tumor phenotypes, impact tumor response to various therapies, 
and influence disease progression [54, 55].
Tumor heterogeneity (Figure 1) encompasses both (i) intertumoral heterogeneity, which 
describes differences between tumors in an individual patient as well as clinical response 
differences between patients with the same tumor subtype, and (ii) intratumoral 
heterogeneity, which refers to the genetic, epigenetic, and phenotypic features that vary 
within malignant cell populations of the same tumor mass [56]. Intratumoral heterogeneity is 
further classified into spatial heterogeneity, which refers to differences between distinct 
anatomical regions or individual cells within a tumor, and temporal heterogeneity, which 
refers to changes in a tumor’s molecular profile and receptor expression over time. An 
example of intratumoral spatial heterogeneity is the highly discordant HER2 expression 
observed in different areas within a single biopsy from HER2-positive metastatic breast 
cancer patients (Figure 3a) [57]. Temporal heterogeneity can be observed for relapsed 
lesions that exhibit a disparate molecular profile, compared to their original tumor.
In addition to morphological and spatiotemporal variations within the same tumor or 
between primary tumors, tumor heterogeneity can also directly result from metastasis. 
Metastatic heterogeneity (Figure 2) has been observed to include (i) discordant biomarker or 
receptor expression between metastases arising from distinct subclonal populations in the 
primary tumor (“intermetastatic” heterogeneity) and (ii) heterogeneity within individual 
metastases (“intrametastatic” heterogeneity), which may have a substantial impact on 
therapeutic outcome [7, 52, 56, 59, 60]. For example, Gerlinger et al. reported a case of 
intrametastatic heterogeneity in which significant changes in the mutational profiles of 
spatially separated biopsy samples from primary renal-cell carcinomas and metastases were 
identified using next-generation sequencing [61]. Additionally, Albino et al. observed 
intermetastatic heterogeneity in a melanoma patient whose multiple metastases displayed 
contrasting morphologies and surface antigen expression [60]. Other studies have also 
investigated variable estrogen, progesterone, and HER2 receptor expression between 
primary breast tumors and metastases, with discordance rates that varied greatly from 18% 
to 54% [52, 62, 63]. Additional types of heterogeneity include non-genetic phenotypic and 
functional heterogeneity [63] and tumor microenvironment heterogeneity [52, 53]. Because 
tumor cells interact with their environment, tumor microenvironment heterogeneity exerts a 
crucial influence on disease progression. For example, the heterogeneous distribution of 
stromal cells, extracellular matrix organization, and especially hypoxic regions within the 
tumor microenvironment may promote metastasis and development of drug resistance [52].
Tumor heterogeneity has been reported in a wide range of human tumors such as breast [52, 
57], non-small cell lung [64, 65], ovarian [52, 58, 66, 67], prostate [52, 68], and lymphoma 
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[69] and poses a significant challenge for diagnosis, prognosis, and efficacy of molecularly-
targeted therapies (Figure 3b) [58, 70]. The presence of heterogeneous cancer cell 
populations within tumors will likely limit the efficacy of any therapeutics targeted against 
any single tumor-associated receptor, leading to poor/varied outcomes, including cancer 
recurrence and therapeutic resistance [6, 56]. For example, the heterogeneous expression of 
programmed death 1 (PD-1) was reported in two distinct T-cell subpopulations and 
differentially impacted survival in patients with follicular lymphoma [69]. Similarly, 
heterogeneous HER2 expression in breast cancer has prompted treatment stratification in the 
clinic based on receptor expression [52]. Indeed, intratumoral HER2 heterogeneity, both 
genetic and spatial, affected the trastuzumab treatment responses and survival of patients 
with HER2-positive metastatic breast cancer [57]. Only a small fraction of trastuzumab-
treated patients achieved complete disease eradication, and the majority of patients 
developed relapsed tumors that were resistant to trastuzumab therapy due to the proliferation 
of HER2-negative breast cancer cells.
In addition to therapy with monoclonal antibodies such as trastuzumab, variable target 
receptor expression in heterogeneous tumors also presents a critical bottleneck for actively 
targeted drug delivery systems. The common active targeting approach, in which drug-
loaded particles are surface modified with a single ligand group, cannot target and facilitate 
intracellular delivery to the full diversity of malignant cells. One potential strategy is the 
administration of a cocktail of single-ligand particles. Unfortunately, this would pose 
considerable challenges and substantial cost burden in the context of particle formulation 
and complexity in clinical evaluation [47], which has generally limited particles to one or 
two distinct targeting ligand groups. More importantly, a single universal targeted 
nanoparticle cocktail for all patients is unlikely to succeed due to interpatient heterogeneity; 
inadequate levels or the complete lack of corresponding target cells for a significant fraction 
of the ligand-modified particles could lead to increased hepatic and splenic biodistribution 
and, correspondingly, reduced tumor accumulation. Alternatively, multiple different 
targeting ligands could be theoretically conjugated onto the surface of a single nanoparticle. 
However, as discussed above, increased density of ligands beyond a particular threshold will 
likely trigger rapid MPS clearance of the particles.
Pretargeted radioimmunotherapy (PRIT)
The discovery that human tumor-associated antigens could be used as targets for antibodies 
to differentiate tumors from normal tissue helped spawn the field of monoclonal antibody 
(MAb)-based immunotherapy of cancer. The multiple applications of cancer immunotherapy 
include radioimmunotherapy (RIT) (Figure 1b), which uses radioisotope-conjugated Mabs 
to treat radiosensitive tumors such as non-Hodgkin’s lymphoma (NHL) [71]. Unfortunately, 
the therapeutic efficacy of RIT is limited by the long circulatory half-life of many MAbs, as 
well as high non-specific deposition of the MAbs in normal organs, resulting in low tumor-
specific delivery of radiation and significant toxicity [72].
To overcome the shortcomings of radioimmunotherapy (RIT), many researchers have 
adopted a multistep approach (Figure 1d) to more specifically deliver radionuclides to tumor 
cells by first injecting BsPs that contain a tumor cell binding domain and an effector binding 
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domain. Subsequently, radiolabeled effector molecules are introduced and interact with 
BsPs bound on the surface of tumor cells. Such an approach has been termed pretargeted 
radioimmunotherapy (PRIT) [73, 74]. Because the BsPs are non-radioactive and the 
radiolabeled effector molecules typically consist of modified small molecule metal chelators 
that can be rapidly cleared, PRIT can significantly improve the therapeutic index of 
radioisotope treatment compared to RIT [72, 75, 76], as well as increase the maximum 
tolerated dose for radionuclides [74]. Pagel et al. demonstrated that anti-CD45 PRIT 
improved the specificity of radiation delivery to leukemia in a rodent model, delivering 
twice as much radiation to bone marrow and five times more activity to the spleen than 
conventional RIT [77, 78]. In vivo PRIT was able to mediate broad tumor growth 
suppression and prolonged survival with the use of BsPs against receptors expressed at 
different levels on lymphoma cells, with CD20 and HLA-DR proving to be superior targets 
compared to CD22 [79, 80]. CD38-specific PRIT achieved tumor-to-blood ratios as high as 
638:1 after 24 hours for a multiple myeloma model, compared to a ratio of ∼1:1 with 
conventional RIT [81]. Subbiah et al. reported that treating athymic mice bearing Ramos 
human Burkitt’s lymphoma xenografts with a pretargeted system consisting of anti-CD20 
scFv-conjugated streptavidin (SA) and 90Y-DOTA-biotin cured 100% of mice with 
allowable toxicity, whereas conventional RIT with 90Y-1F5 at the same dose produced no 
cures, generated profound pancytopenia, and was lethal to all mice [82]. Zhang et al. 
demonstrated that both 90Y-DOTA-biotin and 213Bi-DOTA-biotin could both be used in 
combination with anti-CD25 scFv-conjugated SA for PRIT of a murine T-cell lymphoma 
xenograft model, with the beta-emitter 90Y curing 10 of 10 mice and alpha-emitter 213Bi 
curing 7 of 10 mice [83].
These encouraging results with PRIT studies in animal models led to clinical studies of 
PRIT, which have yielded promising results with reasonable tumor response rates and 
limited toxicity [84]. Forero et al. evaluated the pharmacokinetics and immunogenicity of an 
anti-CD20 scFv-SA conjugate in 15 patients with NHL [85]. Although the complete 
remission rate was low (2 of 15), the majority (12/15) patients exhibited no signs of 
hematologic toxicity, suggesting that the dose of radionuclide could be further increased. 
Another phase I/II PRIT clinical trial was performed using a chimeric anti-CD20 IgG-SA in 
combination with 90Y-DOTA-biotin. Six of seven NHL patients demonstrated significant 
tumor regression, with an estimated tumor-to-whole body dose ratio of 38:1. While six of 
the ten patients developed humoral responses to streptavidin, the transient nature of the 
responses appeared to result in no significant long-term effects [86, 87]. Kraeber-Bodere et 
al. evaluated the therapeutic efficacy of PRIT using a bispecific monoclonal antibody that 
binds to carcinoembryonic antigen (CEA) and to a 131I-labeled effector molecule for PRIT 
of medullary thyroid cancer. Of the 17 patients treated, 4 reported pain relief, 5 
demonstrated minor tumor responses, and 4 achieved biological responses (decrease in 
thyrocalcitonin); however, 9 patients also generated human anti-mouse antibodies [88–90].
While PRIT has led the way in preclinical and clinical studies of pretargeting, it is important 
to note that the applications for pretargeted strategies extend far beyond radiotherapy. For 
example, solid cancers, which will account for more than 90% of all newly diagnosed cancer 
cases and deaths in the United States in 2015 [91], are significantly more resistant to 
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radioimmunotherapy compared to hematological malignancies such as NHL. To date, little 
is known about whether the pretargeting approach can enhance the delivery of other 
therapeutic agents such as nanoparticle drug carriers that can encapsulate and slowly release 
chemodrugs to solid tumors.
Pretargeted drug delivery to heterogeneous tumors
The growing interest in precision/personalized medicine, coupled with the incomplete 
treatment of heterogeneous cancers using common passively or single-ligand targeted 
therapies that can give rise to recurrent, more aggressive, and/or drug-resistant tumors [7, 
56] highlights the need for alternative nanoparticle targeting strategies to improve treatment 
responses. The modular nature of pretargeted systems is particularly useful in addressing the 
challenge of and many barriers to effective drug delivery to heterogeneous tumors [52] 
because it enables pretargeted systems to be targeted to new or different tumor antigens by 
simply modifying the tumor binding domain of BsPs, as opposed to direct, ligand-based 
targeting systems that would require the formulation of a new nanoparticle system. This 
flexibility is expected to markedly reduce the production costs and complexity, as well as 
the potential regulatory burden, for pretargeted nanoparticles. Another equally appealing 
feature of pretargeting is the ability to pretarget multiple receptors simultaneously. The 
administration of a cocktail of pretargeting BsPs that can all bind to the same drug carrier 
could in theory enable the delivery of a drug carrier to the full spectrum of a patient’s cancer 
cells (Figure 4). Drug cocktails containing mixtures of different MAbs have already been 
applied to cancer therapy, with one combination of pertuzumab, trastuzumab, and docetaxel 
significantly improving the overall survival of patients with HER2-positive breast cancer 
[92]. Antibody mixtures have also been used for in vitro and in vivo imaging and diagnosis 
of tumors [93, 94]. Additionally, pretargeting with individual or mixed BsPs was able to 
differentially label a range of human tumor cell lines in vitro (Figure 5a) [95, 96]. To our 
knowledge, no studies have been published on the simultaneous use of multiple pretargeting 
BsPs to enhance nanoparticle delivery to date, although Khaw et al. did report the receptor-
dependent efficacy of doxorubicin nanoparticles pretargeted with anti-HER2 affibody-based 
BsPs in a dual tumor model [97]. In that study, tumor growth inhibition was achieved for 
HER2-positive BT-474 breast cancer tumors, while the HER2-negative BT-20 breast cancer 
tumors were simultaneously unresponsive to the treatment, further emphasizing the 
opportunity for improved cancer treatment through appropriate targeting of all tumor cell 
populations.
Biological and pharmaceutical aspects and considerations of pretargeted 
drug delivery
As multicomponent systems, the potential arsenal of pretargeted therapies is sizeable and 
highly diverse. Thus, many features (e.g., choice of target receptor/antigen, binding pair 
technology, and drug carrier) must be taken into account when developing a pretargeted 
drug delivery system to maximize transport of drug cargo to target cells and overall 
therapeutic efficacy. Because only a few publications have evaluated the use of pretargeting 
for nanoparticle delivery, the majority of the current knowledge about optimal pretargeted 
conditions have been gleaned from in vivo PRIT studies, but, due to the overlap of 
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components for multistep targeting approaches (Figure 1d & e), many of the lessons learned 
from PRIT likely apply to pretargeted nanocarriers.
Binding pairs
A key consideration of any pretargeted delivery approach is the binding interaction between 
the pretargeting BsP and nanoparticle effector, as the affinity of the binding pair directly 
influences the capture and retention of the drug carrier at the tumor site. In addition, the 
immunogenicity of the BsP and its interactions with endogenous ligands can also alter the 
efficacy of pretargeted therapies [71].
The first binding pairs used in pretargeted systems were based on antibody-hapten 
interactions. In 1985, Reardan et al. reported the development of antibodies against indium 
chelates of EDTA, and suggested the possibility of bispecific antibodies that can 
simultaneously recognize target antigens and metal chelates [72, 98]. Soon afterwards, 
Goodwin et al. developed an early pretargeted imaging approach using a murine tumor 
model through the injection of anti-chelate antibodies, followed by the administration of a 
radiolabel [99]. Since then, a number of antibodies against various haptens have been 
utilized for binding to effector molecules, including anti-DTPA complex [100, 101], anti-
peptide [102–104], anti-methotrexate [105], and anti-cotinine antibodies [106]. In addition 
to bispecific antibodies [101, 102, 107], a range of antibody fragments and derivatives have 
been developed as pretargeting BsPs [71, 106, 108]. Most antibodies, including those used 
to capture radioisotope-carrying effector molecules in PRIT, exhibit nanomolar to high 
picomolar affinity (KD ∼10−7–10−10 M) for the antigen target on the surface of cancer cells 
[98, 105, 109]. Because PRIT typically uses single radionuclide-loaded agents, the 
improvement of antibody-hapten binding through multivalency can significantly enhance the 
specificity of radioisotope localization and retention in tumor sites [102, 108, 109]. For 
example, the application of pretargeted bivalent haptens, termed the affinity enhancement 
system (AES), was able to improve the tumor biodistribution of bivalent 111In-diDTPA by 
more than 7-fold compared to monovalent 111In-DTPA (tumor biodistribution: 52.9% vs. 
7.6% ID/g at 1 h and 92.5% vs. 0.9% ID/g at 72 h, respectively) [110].
As a binding pair with one of the strongest noncovalent binding affinities (KD ∼10−14 ��
10−15 M), the streptavidin (SA)-biotin system was quickly adopted by the pretargeting field 
[111, 112]. Additionally, SA is a tetravalent protein and could enable the capture of multiple 
biotinylated drug molecules. SA and biotin can be attached to tumor-specific pretargeting 
proteins and/or effector molecules through a variety of methods, including direct 
conjugation [82, 113, 114], genetic engineering of fusion proteins [115–117], and enzymatic 
conjugation [118]. While SA-based PRIT systems have demonstrated increased tumor 
specificity and higher therapeutic indices relative to directly targeted systems [82, 117] and 
have even been evaluated in clinical trials [85, 114, 119], the immunogenic nature of SA, a 
bacterial protein, represents a major challenge to widespread clinical use of SA-biotin 
binding pairs [85, 87]. The immunogenicity of SA can be reduced through site-specific 
mutations [120, 121], although it remains unclear whether these SA mutants will be 
sufficiently hypoimmunogenic to allow for repeated dosing in humans. The problem of 
interference from endogenous biotin [122], which necessitates the use of biotin-free feed for 
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in vivo studies, could also be potentially addressed by SA mutants that selectively bind bis-
biotin instead of biotin [123, 124]. Other proteins that naturally bind to specific substrates 
(e.g., enzymes) can also be modified to bind to exogenous molecules for use in pretargeting, 
although only a few such systems have been reported in the literature [125, 126].
The majority of published pretargeted and multistep targeting systems utilize antibody-
hapten or protein-ligand interactions, but research in areas such as complementary synthetic 
nucleic acids and peptides and bioorthogonal chemistry continues to generate novel classes 
of binding pairs. Morpholinos (MORFs) are the most popular class of synthetic nucleic acid 
analogs for pretargeting using complementary nucleic acids and have been evaluated 
preclinically in combination with tumor-specific pretargeting antibodies and a variety of 
radionuclides [127–131]. In addition to relatively low immunogenicity, optimized 
complementary morpholinos exhibit high specificity and binding affinity [132], and the use 
of bivalent MORFs may further enhance affinity [133]. Bioorthogonal chemistry comprises 
reactions that can rapidly occur in a living system with high selectivity and without any off-
target reactions or toxicity. These properties enable pretargeting using small molecule 
binding pairs with low immunogenicity, although the relative merits of different 
bioorthogonal chemistries vary based on reaction kinetics, complexity of synthesis, and 
stability of the resulting conjugate (see refs [71, 134, 135]). Rossin et al. demonstrated the 
feasibility of using “click” chemistry for pretargeting of radioisotopes in vivo by treating 
tumor-bearing mice with an anti-TAG72 antibody (CC49) modified with trans-cyclooctene 
(TCO), which then reacted with 111In-tetrazine (111In-Tz) administered 24 h later [136]. The 
CC49-TCO predosed mice exhibited a tumor uptake of 4.2% ID/g and tumor-to-muscle 
(T/M) ratio of 13.1, compared to tumor uptake and T/M ratios of 0.3% ID/g and 0.5 and 1% 
ID/g and 2.1 for unmodified CC49 and control Ab-TCO groups, respectively. Further 
preclinical studies have confirmed the utility of TCO-tetrazine and other bioorthogonal 
chemistries for tumor imaging and treatment [71, 137–139].
While all of the aforementioned classes of binding pairs have also been used in the 
pretargeting of nanoparticles and other potential drug carriers [95, 140–142], the ability of 
pretargeted systems to actually deliver therapeutics to tumor cells has only been evaluated in 
a few studies [97, 143–145]. Pretargeted poly-lysine polymers [146], liposomes [147], and 
carbon nanotubes [148] have been used to deliver higher doses of encapsulated or 
conjugated radionuclides to both solid tumor and hematologic cancer cells, suggesting that 
the application of nanocarriers could further improve the efficacy of PRIT. In the context of 
cancer chemotherapy, pretargeted biotinylated polymeric nanoparticles loaded with 
pactilaxel (PTX) increased the in vitro cell killing of glioma and breast cancer cells, relative 
to free drug or Taxol and nontargeted nanoparticles [143, 144]. The injection of an anti-
HER2 affibody-anti-DTPA Fab complex (BAAC) 8 h prior to the administration of 99mTc-
DTPA-succinylated polylysine enabled the specific labeling of tumors (5.3% ID/g vs. 0.5% 
ID/g for anti-DTPA Fab-pretargeted particles) [97]. BAAC pretargeting of doxorubicin- and 
DTPA-conjugated polyglutamic acid produced tumor growth inhibition results that were 
similar to those of free doxorubicin, but pretargeting through the combination of BAAC and 
polymer-drug conjugate minimized weight loss in mice relative to the free drug treatment 
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[97], underscoring the ability of pretargeting to improve the therapeutic index of 
chemotherapeutics in vivo.
Although BsP considerations such as immunogenicity and competition with endogenous 
ligands apply to both PRIT and pretargeted nanoparticles, other features and characteristics 
of binding pairs required for pretargeted drug delivery systems may differ from those for 
pretargeting based on small molecule effectors. Nanoparticles are inherently highly 
multivalent due to their large surface area, which allows the grafting of tens to possibly 
thousands of a given binding partner moiety. Thus, BsPs with lower affinity to a hapten may 
still be able to capture hapten-coated nanoparticles with high avidity compared to individual 
radiolabeled haptens. However, as is the case with actively targeted systems, the 
incorporation of peptides, nucleic acids, proteins and other macromolecular components 
onto drug carrier particles could negatively impact their circulation kinetics and efficiency 
of extravasation into tumors. For highly asymmetric binding pairs that consist of a large 
protein and a smaller moiety (e.g., SA-biotin, antibody-hapten), the smaller, the more 
immunologically inert moiety should be assigned to the effector nanoparticle, rather than the 
BsP, to minimize MPS clearance. Steric considerations may further support the modification 
of drug carriers with smaller BsP-binding components. For instance, Haun et al. reported 
that, in addition to relatively to providing a 10- to 15-fold increase in cell binding relative to 
directly targeted iron oxide nanoparticles, a pretargeted antibody-TCO/Tz-NP system 
demonstrated significantly higher fluorescent labeling of various tumor cell lines, compared 
to an antibody-biotin/avidin-NP system [95]. The authors attributed this difference to the 
large footprint of avidin (∼67 kDa) on the particles, which likely resulted in the reduced 
accessibility and valency of biotin-binding sites. The use of a PEG spacer for TCO-antibody 
modificiation also improved the pretargeting of quantum dots by reducing masking of 
reactive groups [149].
Target antigen(s)
A diverse array of receptors and other antigens overexpressed on tumor cells have been 
exploited for active targeting of nanoparticles and for RIT [1, 150]. In contrast, the number 
of target cancer antigens/receptors suitable for pretargeted approaches is certainly more 
limited. The multistep nature of pretargeting requires that the tumor cell-binding BsP must 
remain on the tumor cell surface to capture subsequently injected effector drug carriers. 
Indeed, the majority of PRIT studies to date utilize BsPs that target epitopes generally 
considered to be non-internalizing, including CD20, CD45, TAG72, and CEA [75, 85, 115, 
133, 142, 145, 148]. However, Liu et al. observed the fairly rapid internalization of 
radiolabeled anti-TAG72 and anti-CEA antibodies, with about 60% of the antibodies 
internalized by LS174T colon carcinoma cells after 5 h [128]. Similarly, although HER2 is 
thought to be an internalizing epitope, pretargeting using bispecific antibodies against HER2 
mediated enhanced tumor accumulation in vivo [97, 106, 151]. Whether these apparently 
counterintuitive results are due to differences in antibody internalization kinetics between in 
vitro and in vivo conditions (e.g., differences in receptor density, receptor turnover rates, 
and/or endocytosis and cell signalling pathways), dosing of the pretargeting molecules at 
sufficiently high levels that compensate for loss due to antigen/BsP internalization, or other 
factors remains unknown.
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While the pretargeting molecule should initially remain non-internalized, many therapeutics 
require intracellular delivery to be effective and/or exhibit maximal potency; thus, the ideal 
pretargeted nanoparticle must be internalized only after binding of the drug carrier (Figure 
1). Although internalization mediated by a non-internalizing pretargeting molecule may 
appear paradoxical, cellular entry could be achieved by relying on the eventual endocytosis 
of bound receptors or, more preferably, through multivalent nanoparticle binding effects 
such as crosslinking of receptors. Mulvey et al. observed that anti-A33-MORF conjugates 
remained stably on the surface of LS174T cells for up to 24 h, and that the addition of 
complementary MORF-modified carbon nanotubes resulted intracellular punctate staining 
indicative of internalization (Figure 6) [148]. In contrast, free complementary MORFs failed 
to induce internalization (Figure 6). Gunn et al. similarly reported that iron oxide 
nanoparticles pretargeted to CD20-expressing cells were found in endosomes, as visualized 
by transmission electron microscopy [140]. These results suggest that BsPs that bind non-
internalizing epitopes can still facilitate pretargeted intracellular delivery of nanocarriers.
Pharmacokinetics and biodistribution
The theoretical improvements in the therapeutic index of drug delivery systems that can be 
achieved using pretargeting are based on the decoupling of the tumor targeting vs. drug-
carrying functions. This in turn implies that the efficacy of a given pretargeted system is 
dependent on the pharmacokinetics and biodistribution of each component. One of the most 
important requirements is that the pretargeting BsPs are maximally cleared from systemic 
circulation prior to the administration of the drug carrier, particularly for pretargeted systems 
based on high affinity binding pairs such as SA-biotin. Indeed, SA-coated liposomes were 
detectable in circulation for at least 24 h after i.v. administration in mice, whereas SA-coated 
liposomes premixed with biotinylated anti-Thy1.2 antibodies prior to dosing were rapidly 
cleared within 4 h [145], illustrating the potential problem of circulating BsP binding to 
effector nanoparticles before the particles can extravasate into the tumor. Correspondingly, 
Karacay et al. found that, while an anti-CEA IgG x anti-DTPA Fab’ conjugate demonstrated 
superior tumor labeling relative to F(ab’)2 x Fab’ and Fab’ x Fab’ constructs, the F(ab’)2 x 
Fab’ conjugate provided better pretargeting of a divalent DTPA peptide due to the high 
residual blood concentration of IgG x Fab’ even 6 days after administration [100]. In order 
to simultaneously optimize tumor distribution and retention along with systemic clearance, a 
variety of techniques have been used to modify the size, valency, and composition of 
pretargeting BsPs, including the “dock-and-lock” method [152, 153] and fusion protein 
engineering [85, 115, 125].
An alternative approach to ensure elimination of residual pretargeting molecules from the 
systemic circulation is the use of clearing agents (CAs) prior to the dosing of nanoparticles 
or therapeutic effector molecules. These multivalent agents are generally designed to bind 
tightly to the pretargeting molecules and are sufficiently large enough to be rapidly cleared 
from the systemic circulation without extravasating into tumors. Previously reported CAs 
include secondary antibodies [154] and avidin [155], as well as biotinylated and 
galactosylated human serum albumin [156] and dendrimers [78, 115]. The use of a CA can 
effectively purge circulating BsP molecules (reducing blood concentrations by up to 10-
fold) without affecting the tumor accumulation of pretargeting molecules [115, 155, 157]. 
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The potential drawback of CA use is the addition of yet another dose and wait step to the 
course of therapy. For example, the use of CAs with the sequential combination of 
biotinylated antibodies, SA, and finally biotinylated radionuclide resulted in a 5-step PRIT 
strategy (biotinylated MAb/avidin CA/streptavidin/biotinylated CA/biotinylated 
radiolabeled chelate) [158, 159] Although the radioimmunotherapy was well-tolerated and 
effective in glioma patients, with a median survival of 33.5 months (compared to 8 months 
for untreated control patients) in a nonrandomized phase I/II study, the need for several 
parenteral injections to deliver a single dose of radiation or drug not only introduces a high 
degree of complexity but also increases the cost of therapy. A simpler 2-step approach is 
likely far more preferable, particularly when using antibody-hapten binding pairs. These 
pretargeted systems appear to better tolerate the presence of minute amounts of uncleared 
pretargeting BsP, possibly due to the lower affinity and the dissociation of BsP-effector 
complexes formed in the blood [160].
The pharmacokinetics of the pretargeted drug carrier must also be taken into consideration. 
Because the commonly utilized pretargeting molecules are generally much smaller than 
nanoparticle drug carriers, the overall tumor distribution and accumulation of pretargeted 
systems is therefore limited by the circulation and extravasation kinetics of the drug carrier. 
To minimize premature elimination from the circulation and maximize tumor accumulation, 
drug carriers should be effectively coated with stealth polymers, whereas the use of of 
bulky, charged, and/or hydrophobic moieties to facilitate particle binding to the pretargeting 
molecule should be avoided if possible. As noted in the previous section, this latter 
requirement may affect the choice of binding pair technology for pretargeted nanoparticle 
systems, as well as the assignment of binding pair components to the BsP and effector 
particle. For example, if using a SA-biotin binding system, the nanoparticle should be 
biotinylated, with the SA component in the pretargeting molecule, rather than vice versa.
Challenges and unknowns
The combination of a bispecific pretargeting cocktail with nanoparticle drug carriers is a 
promising but vastly underexplored approach to targeting nanoparticles to heterogeneous 
tumors. Thus, many aspects of this proposed strategy must be rigorously evaluated to 
confirm its suitability for clinical applications.
One of the major challenges is that a greater dose of pretargeting BsP could potentially 
reduce nanoparticle binding and accumulation to tumor cells. Because tumor receptor 
expression varies both spatially and temporally, and receptor testing is typically performed 
on primary tumor biopsies obtained close to the time of diagnosis, “personalized” 
pretargeting cocktails based on those patient biopsy results is unlikely to capture the full 
heterogeneity of cancer cells in a patient over time, particularly for relapsed and/or highly 
metastatic tumors [6]. Thus, truly personalized pretargeted therapy would greatly benefit 
from improvements in noninvasive molecular profiling of cancers [56, 161]. As an 
alternative to the fine-tuning of individual pretargeting cocktails, the properties of BsPs 
could be optimized to allow rapid elmination of non-binding BsPs from the circulation. The 
mechanism, rate, and extent of pretargeting BsP clearance with and without the use of 
clearing agents must be carefully investigated, particularly since Pagel and colleagues 
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observed that the administration of high doses of MAb-SA conjugates specific to receptors 
poorly expressed on certain lymphoma tumors overloaded the capacity of mice to 
hepatically clear MAb-SA/CA complexes, resulting in low tumor-to-normal organ 
biodistribution ratios and toxicity [79, 162]. The increased doses of total protein required for 
a cocktail pretargeting approach may also affect the immunogenicity of the pretargeting 
BsPs used.
Additionally, the limited number of appropriate target receptor/antibody combinations that 
have been evaluated for pretargeting to date may hinder the development of useful 
pretargeting cocktails. The main driving forces behind the discovery of novel tumor-specific 
receptors and their corresponding ligands/antibodies are diagnostic biomarkers, imaging 
applications and targeted drug and MAb therapy. Unfortunately, few of these studies focus 
on non-internalizing antibodies, a critical requirement of pretargeting. However, the use of 
(pre)clincially validated ligands and therapeutic MAbs could lead to fortuitous combinations 
for pretargeting. For example, anti-CD20 MAbs can induce apoptosis clinically [163], and 
anti-CD20 Fab’ fragments linked to MORFs have been found to also induce apoptosis of B-
cell lymphomas in vitro and inhibit development of diffuse tumors in vivo upon crosslinking 
by cMORF-modified polymers [141]. The use of antibodies with inherent therapeutic 
efficacy for pretargeting of drug carriers could allow for synergistic treatment effects. 
Improvements in the generation of diverse bispecific proteins and antibodies will also 
certainly expand the diversity of available pretargeting molecules [152, 153, 164].
Other concerns regarding the application of pretargeted drug delivery systems include the 
clinical feasiblity of multistep parenteral injections and the poor tumor accumulation of 
many drug carriers in patient tumors. Similar to passively and actively targeted 
nanoparticles, the tumor accumulation of pretargeted drug carriers would still rely on the 
EPR effect [145], which has been found to be highly variable [36].
Conclusion
Despite marked advances in biotechnology, nanotechnology and drug delivery, effective 
therapy for cancer remains exceedingly challenging, with few treatment options that can 
provide durable suppression or elimination of the tumor without resulting in eventual 
recurrence and/or the development of drug-resistant tumors. Emerging insights into tumor 
physiology have underscored tumor heterogeneity as one of the key bottlenecks to targeted 
therapy. The concept of pretargeting using a cocktail of bispecific pretargeting proteins 
combines the strengths of precision medicine and personalized medicine by offering the 
potential to deliver nanoparticle therapeutics to diverse cell populations while avoiding the 
pharmacokinetic pitfalls typically associated with actively targeted nanoparticles. Although 
the radioimmunotherapy field has offered substantial evidence supporting the pretargeting 
strategy, its application for enhancing targeted delivery of nanoparticle therapeutics remains 
underexplored to date. We believe further rigorous evaluation of pretargeted NP systems is 
both warranted and needed to confirm whether pretargeting can indeed prove superior to 
current passive and active targeting approaches.
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Strategies for the delivery of nanoparticle drug carriers and/or radioisotopes to tumor cells 
include a) non-targeted, b & c) directly targeted (1-step), and d & e) pretargeted (multistep) 
approaches. a) Passively targeted nanoparticles coated solely with stealth polymers typically 
do not exhibit specific interactions with tumor cells. b) Radioimmunotherapy (RIT) uses 
radiolabeled tumor receptor-specific antibodies to deliver therapeutic doses of radiation to 
target cells. c) Modification with receptor-specific ligands allows the active targeting of 
nanoparticles (NPs) to tumor cells, which commonly induces receptor-dependent 
internalization. d) Pretargeted radioimmunotherapy (PRIT) splits tumor targeting and 
radioisotope delivery into sequential steps: 1) binding of bispecific proteins (BsPs) to target 
receptors and 2) binding of radiolabeled effector molecules to the BsPs. e) For pretargeted 
drug delivery systems, 1) bispecific proteins (BsPs) bind target receptors, and 2) a drug-
loaded effector nanoparticle binds to the BsPs, which should ideally result in internalization.
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Different types of tumor heterogeneity. Spatial heterogeneity refers to differences between 
distinct anatomical regions or individual cells within a tumor, while temporal heterogeneity 
illustrates changes in a tumor’s molecular profile over time. Intermetastatic heterogeneity 
arises from distinct subclonal populations in the primary tumor, and intrametastatic 
heterogeneity reflects the discordant molecular profiles of cells within individual metastases.
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a) Spatial heterogeneity in HER2 expression between three different areas of an invasive 
ductal carcinoma biopsy sample. HER2 amplification was confirmed using 
immunohistochemistry (IHC) and silver in situ hybridization (SISH). H&E, ×200; IHC, 
×200; SISH, ×400. Reprinted with permission from Lee et al. [57]. b) Progression free 
survival (top) and overall survival (bottom) of high-grade serous ovarian cancer patients 
treated with platinum-based chemotherapy and surgery, stratified by degree of clonal 
expansion (CE). CE reflects the accumulation of mutations that promote cell expansion into 
varying subclonal populations from the original cell. Higher CE is correlated with divergent 
subclonal populations and thus greater tumor heterogeneity. Reprinted with permission from 
Schwarz et al. [58].
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Pretargeted delivery of nanoparticles (NPs) to heterogeneous tumors. 1) A cocktail of 
bispecific proteins (BsPs) is administered and allowed to fully clear from systemic 
circulation prior to 2) dosing with nanoparticles that can be captured by BsPs on the tumor 
cell surface. To enable effective targeting of multiple tumor cell subpopulations using a 
single nanoparticle, the tumor antigen-binding domain (Figure 1e) of the BsPs can be 
modified to reflect the full diversity of tumor cells, while the effector (NP)-binding domain 
remains the same for all BsPs.
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Diagnostic magnetic resonance profiling of human tumor cell lines, fibroblasts, and 
leukocytes using a pretargeted approach in vitro. The cells were labeled using various trans-
cyclooctene (TCO)-conjugated antibodies followed by tetrazine-modified magneto-
fluorescent nanoparticles (Tz-MFNPs) prior to the measurement of the transverse relaxation 
rate (R2). Figure reprinted with permission from Haun et al. [95].
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Internalization of pretargeted single-walled carbon nanotubes (SWNTs). LS174T (A33-
positive) colon carcinoma cells were preincubated anti-A33 antibodies conjugated to 
morpholino oligonucleotide (anti-A33-MORFs) for 4 h prior to washing and further 
incubation with complementary MORF (cMORF)-SWNT-AlexaFluor 647 or free cMORF-
AlexaFluor 647. Figure reprinted with permission from Mulvey et al. [148].
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